MacroGenics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDMacroGenics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 11% provides fundamental context to the price action. Investors should exercise caution due to high volatility (91% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.33 | +5.62% | ABOVE |
| 50 SMA | $3.95 | +15.57% | ABOVE |
| 100 SMA | $3.33 | +37.44% | ABOVE |
| 150 SMA | $2.76 | +65.54% | ABOVE |
| 200 SMA | $2.48 | +84.30% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MGNX in an uptrend right now?
MGNX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MGNX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is MGNX overbought or oversold?
MGNX's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is MGNX outperforming the market?
MGNX has a Relative Strength (RS) Rating of 97 out of 99. Yes, MGNX is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is MGNX in its 52-week range?
MGNX is trading at $4.57, which is 90% of its 52-week high ($5.08) and 87% above its 52-week low ($1.29).
How volatile is MGNX?
MGNX has a Beta of 1.30 and 52-week volatility of 91%. It's more volatile than the S&P 500 - expect bigger swings.